|
|
| (One intermediate revision not shown.) |
| Line 3: |
Line 3: |
| | <StructureSection load='4jfx' size='340' side='right'caption='[[4jfx]], [[Resolution|resolution]] 1.95Å' scene=''> | | <StructureSection load='4jfx' size='340' side='right'caption='[[4jfx]], [[Resolution|resolution]] 1.95Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[4jfx]] is a 5 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4JFX OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4JFX FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4jfx]] is a 5 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4JFX OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4JFX FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PG4:TETRAETHYLENE+GLYCOL'>PG4</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.95Å</td></tr> |
| - | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=PTR:O-PHOSPHOTYROSINE'>PTR</scene></td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PG4:TETRAETHYLENE+GLYCOL'>PG4</scene>, <scene name='pdbligand=PTR:O-PHOSPHOTYROSINE'>PTR</scene></td></tr> |
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4jfy|4jfy]], [[4jfz|4jfz]], [[4jg0|4jg0]], [[4jg1|4jg1]]</td></tr>
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4jfx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4jfx OCA], [https://pdbe.org/4jfx PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4jfx RCSB], [https://www.ebi.ac.uk/pdbsum/4jfx PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4jfx ProSAT]</span></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4jfx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4jfx OCA], [http://pdbe.org/4jfx PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4jfx RCSB], [http://www.ebi.ac.uk/pdbsum/4jfx PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4jfx ProSAT]</span></td></tr> | + | |
| | </table> | | </table> |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| Line 22: |
Line 21: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Degrado, W F]] | + | [[Category: Degrado WF]] |
| - | [[Category: Hannigan, B T]] | + | [[Category: Hannigan BT]] |
| - | [[Category: Koerber, J T]] | + | [[Category: Koerber JT]] |
| - | [[Category: Thomsen, N D]] | + | [[Category: Thomsen ND]] |
| - | [[Category: Wells, J A]] | + | [[Category: Wells JA]] |
| - | [[Category: Immmunoglobulin domain]]
| + | |
| - | [[Category: Immune system]]
| + | |
| Structural highlights
Publication Abstract from PubMed
Aberrant changes in post-translational modifications (PTMs) such as phosphate groups underlie a majority of human diseases. However, detection and quantification of PTMs for diagnostic or biomarker applications often require PTM-specific monoclonal antibodies (mAbs), which are challenging to generate using traditional antibody-selection methods. Here we outline a general strategy for producing synthetic, PTM-specific mAbs by engineering a motif-specific 'hot spot' into an antibody scaffold. Inspired by a natural phosphate-binding motif, we designed and selected mAb scaffolds with hot spots specific for phosphoserine, phosphothreonine or phosphotyrosine. Crystal structures of the phospho-specific mAbs revealed two distinct modes of phosphoresidue recognition. Our data suggest that each hot spot functions independently of the surrounding scaffold, as phage display antibody libraries using these scaffolds yielded >50 phospho- and target-specific mAbs against 70% of target peptides. Our motif-specific scaffold strategy may provide a general solution for rapid, robust development of anti-PTM mAbs for signaling, diagnostic and therapeutic applications.
Nature-inspired design of motif-specific antibody scaffolds.,Koerber JT, Thomsen ND, Hannigan BT, Degrado WF, Wells JA Nat Biotechnol. 2013 Aug 18. doi: 10.1038/nbt.2672. PMID:23955275[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Koerber JT, Thomsen ND, Hannigan BT, Degrado WF, Wells JA. Nature-inspired design of motif-specific antibody scaffolds. Nat Biotechnol. 2013 Aug 18. doi: 10.1038/nbt.2672. PMID:23955275 doi:10.1038/nbt.2672
|
